Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype

Renal Cancer would greatly benefit from new therapeutic strategies since, in advanced stages, it is refractory to classical chemotherapeutic approaches. In this context, lysosomal protease cysteine cathepsins may represent new pharmacological targets. In renal Cancer, they are characterized by a higher expression, and they were shown to play a role in its aggressiveness and spreading. Traditional studies in the field were focused on understanding the therapeutic potentialities of cysteine Cathepsin inhibition, while the direct impact of such therapeutics on the expression of these enzymes was often overlooked. In this work, we engineered two fluoromethyl ketone-based Peptides with inhibitory activity against cathepsins to evaluate their potential Anticancer activity and impact on the lysosomal compartment in human renal Cancer. Molecular modeling and biochemical assays confirmed the inhibitory properties of the Peptides against cysteine Cathepsin B and L. Different Cell Biology experiments demonstrated that the Peptides could affect renal Cancer cell migration and organization in colonies and spheroids, while increasing their adhesion to biological substrates. Finally, these peptide inhibitors modulated the expression of LAMP1, enhanced the expression of E-cadherin, and altered Cathepsin expression. In conclusion, the inhibition of cysteine cathepsins by the Peptides was beneficial in terms of Cancer aggressiveness; however, they could affect the overall expression of these proteases.

cysteine cathepsin inhibitors; cysteine cathepsins; lysosome; renal cancer.